VIDEO: Novel combination therapies under investigation for small cell lung cancer

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

As far as combination regimens, there are a handful of combinations that are being done with lurbinectedin. There’s a first-line trial, where in the maintenance setting with atezolizumab, lurbinectedin is being given. There’s combination lurbinectedin plus irinotecan that’s in the LAGOON trial.

That’s a three-arm trial, that also has a lurbinectedin alone arm, and then irinotecan alone arm. What I find really interesting, actually is, those who have not gotten a checkpoint inhibitor to be getting lurbinectedin plus pembrolizumab. And I find that actually to be the more compelling of these trials that I’ve mentioned, in that it is taking patients that are now in the second line, who have not gotten a checkpoint inhibitor.

It’s giving them that cytotoxic, and lurbinectedin that’s more likely to help for a larger number of patients, while also getting that shot at the real leap forward with the durability of the immunotherapy. You know, these are the trials with a cytotoxic that’s being added. As far as combination regimens, you know, most of the trials right now are really single-agent drugs that have novel mechanisms. There’s a recently completed anti-TIGIT plus anti-PD1 in the first-line setting.

That trial was completed and the data is not yet available. It’s still maturing. So, there have been some other combination trials that are not yet reported out. In the limited-stage setting, we have seen the addition of immunotherapy of checkpoint inhibitors with chemo and radiation and that data is still pending. So, we have a lot of studies that have completed accrual and now we’re awaiting data. But, you know, initially I outlined some of the ones that we currently are enrolling.